Long-term Success: Sirolimus-Coated Balloon Angioplasty Shines in SIRONA Trial

Concept Medical Inc. has presented encouraging preliminary 3-year follow-up data from the SIRONA randomised trial at the 2026 Charing Cross Symposium. Sirolimus-coated balloon angioplasty showed superior freedom from reintervention compared to its paclitaxel counterpart, indicating promising durability and long-term efficacy in treating femoropopliteal artery disease.

Concept Medical Inc. unveiled promising 3-year data from the SIRONA randomised trial, highlighting the effectiveness of its sirolimus-coated balloon angioplasty at the Charing Cross Symposium 2026.

Results presented by Principal Investigator Prof. Ulf Teichgräber demonstrated increased freedom from reintervention, suggesting a robust long-term efficacy over paclitaxel-based therapies.

MagicTouch PTA's sustained results in femoropopliteal artery disease underscore its potential as a leading intervention tool, with a balanced safety profile confirming its long-term viability pending further adjudication.